{"id":355,"date":"2016-09-01T13:51:29","date_gmt":"2016-09-01T11:51:29","guid":{"rendered":"https:\/\/m-nc.de\/en\/?page_id=355"},"modified":"2019-02-04T14:36:50","modified_gmt":"2019-02-04T12:36:50","slug":"abgeschlossene-projekte","status":"publish","type":"page","link":"https:\/\/m-nc.de\/en\/abgeschlossene-projekte","title":{"rendered":"Completed Projects"},"content":{"rendered":"

Completed Projects<\/p>\n

Medical Netcare – Management in Health Care<\/font><\/p>\n

Our completed projects<\/font><\/p>\n

line<\/p>\n

fadeIn<\/p>\n

The TEMPO\u00ae<\/sup>-Study<\/b><\/font><\/p>\n

h4<\/p>\n

Being just a start-up, Medical Netcare published the results of the TEMPO\u00ae<\/sup>-study in the journal “Diabetes and Metabolism” (issue 12\/2003). The TEMPO\u00ae<\/sup>-study is highly regarded among diabetologists. It deals with risk profiling, cost analysis and resource optimisation in diabetes treatment. It was the first study ever to prove the advantages of being treated in a medical practice specialising in diabetology. Moreover, a number of different patient (risk) profiles could be defined, which allowed detailed recommendations regarding therapy and treatment strategy. Each risk profile could be related to their direct treatment costs.<\/font><\/p>\n<\/i><\/span>TEMPO\u00ae-Study<\/span><\/a>\n\n

icon-lamp<\/p>\n

\"Tempo-1\"<\/p>\n

top<\/p>\n

fadeIn<\/p>\n

The COMPACT\u00ae<\/sup>-Study<\/b><\/font><\/p>\n

h4<\/p>\n

The COMPACT\u00ae<\/sup>-Study is a medical and pharma-economic analysis comparing the usual insulin therapy to a therapy with pioglitazone. The study deals with topics like insulin resistance and its implications for interventions from a medical and an economic point of view, finally leading to a cost-effectiveness ratio. Amongst other things, the study provides a solid data addendum to view standard therapy proposals (for example in the context of guidelines) in cost-benefit equations.<\/font><\/p>\n

<\/i><\/span>COMPACT\u00ae-Study<\/span><\/a>\n<\/font><\/p>\n

icon-lamp<\/p>\n

\"Compact_klein-1\"<\/p>\n

top<\/p>\n

fadeIn<\/p>\n

The Phazit\u00ae<\/sup>-Study<\/b><\/font><\/p>\n

h4<\/p>\n

In 2003, MNC published the newsletter “pharma-economic surveillance to supplementary insulin therapy” – Phazit\u00ae<\/sup> in collaboration with the Novo Nordisk Pharma GmbH.
\nThe study builds on findings observed in the TEMPO\u00ae<\/sup>-Study. It examines two therapy options in supplementary insulin therapy (SIT), insulin analogues vs. normal insulin, and their effects on effectivity, dosage and costs..<\/font><\/p>\n<\/i><\/span>Phazit\u00ae-Study<\/span><\/a>\n\n

icon-lamp<\/p>\n

\"a_Phazit\"<\/p>\n

top<\/p>\n

fadeIn<\/p>\n

The eAWB\u00a9<\/sup>-Software<\/b><\/font><\/p>\n

h4<\/p>\n

Our eAWB\u00a9<\/sup>-Software supports the Medical Netcare GmbH in various projects.The software enables participating actors to gather data individually aligned with the needs of the respective study. Thereby, data quality and usability are optimized and preferably unaltered results guaranteed.<\/font><\/p>\n<\/i><\/span>more information<\/span><\/a>\n\n

icon-floppy<\/p>\n

top<\/p>\n

fadeIn<\/p>\n

The Benchmark\u00a9<\/sup>-Study<\/b><\/font><\/p>\n

h4<\/p>\n


\nPractitioners can achieve a certified additional qualification “Diabetologist DDG” by the German Diabetes Association (Deutsche Diabetes Gesellschaft, DDG). The Benchmark\u00a9<\/sup>-Study analyses the impact of this additional qualification on structure and process characteristics in outpatient diabetological supply. To this end, more than 400 surgeries with diabetological focus were assigned to subgroups with or without the qualification and then compared. Among other things, it became obvious that the additional qualification “Diabetologist DDG” mainly influences the structure while the case mix is more dependent on the recognition as a medical practice specialising in diabetology.<\/font><\/p>\n<\/i><\/span>Benchmark\u00a9-Study<\/span><\/a>\n\n

icon-chart-bar<\/p>\n

top<\/p>\n

fadeIn<\/p>\n

Evaluating the integrated health care in the Rhineland<\/b><\/font><\/p>\n

h4<\/p>\n

Integrated health care in a German statutory health insurance company (the Allgemeine Ortskrankenkasse (AOK) Rheinland\/ Hamburg) in the Rhineland consisted of 22 locally restricted networks with differing indications. The concept of integrated health care stands for a health care concept connecting every medical sector to each other. For example, general practitioners or specialists collaborate with in-patient facilities, cooperate in their patient\u2019s treatment and possibly even share a common budget.<\/font><\/p>\n<\/i><\/span>more information<\/span><\/a>\n\n

icon-user-add<\/p>\n

top<\/p>\n

fadeIn<\/p>\n

Integrated Care<\/b><\/h4>\n

From 2006 to 2011, MNC managed the scientific monitoring of the integrated health care by a German statutory health insurance, the Allgemeine Ortskrankenkasse (AOK) Rheinland\/ Hamburg, in the Rhineland. Integrated health care in the Rhineland consisted of 22 locally restricted networks with differing indications. The concept of integrated health care stands for a health care concept connecting every medical sector to each other. For example, general practitioners or specialists collaborate with in-patient facilities, cooperate in their patient\u2019s treatment and possibly even share a common budget..<\/p>\n

The following priorities were set for the quality objectives in the “IV”:<\/p>\n